[characterized in that] binding AAV-2 or antigen portions thereof [are bonded] to an activated chromatographic material which comprises antibodies linked thereto and directed against AAV-2, and

[then elution is carried out] eluting said AAV-2 or antigen portions thereof using a solution containing 0.5 to 4.5 m$MgCl_2$.

2 (Amended) The method according to claim 1, wherein said AAV-2 is [either] a wild-type AAV-2 or a recombinantly prepared AAV-2.

3 (Reiterated) The method according to claim 1 or 2, wherein the chromatographic material is selected from the group consisting of agarose gels, dextran gels, cellulose gel matrices and acrylamide gel matrices.

4. (Amended) The method according to [any one of claims 1 to 3] claim 1 or 2, wherein the chromatographic material carries a ligand suitable for [bonding] binding proteins [, particularly antibodies].

5. (Amended) The method according to [any one of claims 1 to 4] claim 1 or 2, wherein the chromatographic material is CNBr-activated sempharose® or NHS-activated sempharose®.

6 (Amended) The method according to [any one of claims 1 to 5] claim 1 or 2, wherein the [elution] solution contains 2 to 3 M $MgCl_2$.

7. (Amended) The method according to [any one of claims 1 to 6] claim 1 or 2, wherein the sample containing the AAV-2 [and rAAV-2, respectively,] is a cell culture supernatant or cell extracts.

8. (Amended) The method according to [any one of claims 1 to 7] claim 1 or 2, wherein the antibody directed against AAV-2 is A20 (DSM ACC2194).